Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences Inc (NQ: XBIO )

4.530 -0.045 (-0.98%)
Streaming Delayed Price Updated: 3:48 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenetic Biosciences Inc

< Previous 1 2 Next >
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Via ACCESSWIRE
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Via ACCESSWIRE
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Via ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Via ACCESSWIRE
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
Via ACCESSWIRE
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology... 
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET - 
From JTC Team, LLC
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.